JVI Figure table search 04
Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Marusic, C.
Right arrow Articles by Capone, I.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Marusic, C.
Right arrow Articles by Capone, I.

 Previous Article  |  Next Article 

Journal of Virology, September 2001, p. 8434-8439, Vol. 75, No. 18
0022-538X/01/$04.00+0   DOI: 10.1128/JVI.75.18.8434-8439.2001
Copyright © 2001, American Society for Microbiology. All rights reserved.

Chimeric Plant Virus Particles as Immunogens for Inducing Murine and Human Immune Responses against Human Immunodeficiency Virus Type 1

Carla Marusic,1 Paola Rizza,2 Laura Lattanzi,2 Camillo Mancini,1 Massimo Spada,2 Filippo Belardelli,2 Eugenio Benvenuto,1,* and Imerio Capone2,*

Divisione Biotecnologie e Agricoltura, ENEA, 00060 Rome,1 and Laboratorio di Virologia, Istituto Superiore di Sanità, 00161 Rome,2 Italy

Received 23 April 2001/Accepted 12 June 2001

The high-yield expression of a neutralizing epitope from human immunodeficiency virus type 1 (HIV-1) on the surface of a plant virus and its immunogenicity are presented. The highly conserved ELDKWA epitope from glycoprotein (gp) 41 was expressed as an N-terminal translational fusion with the potato virus X (PVX) coat protein. The resulting chimeric virus particles (CVPs), purified and used to immunize mice intraperitoneally or intranasally, were able to elicit high levels of HIV-1-specific immunoglobulin G (IgG) and IgA antibodies. Furthermore, the human immune response to CVPs was studied with severe combined immunodeficient mice reconstituted with human peripheral blood lymphocytes (hu-PBL-SCID). hu-PBL-SCID mice immunized with CVP-pulsed autologous dendritic cells were able to mount a specific human primary antibody response against the gp41-derived epitope. Notably, sera from both normal and hu-PBL-SCID mice showed an anti-HIV-1-neutralizing activity. Thus, PVX-based CVPs carrying neutralizing epitopes can offer novel perspectives for the development of effective vaccines against HIV and, more generally, for the design of new vaccination strategies in humans.

* Corresponding author. Mailing address for Eugenio Benvenuto: ENEA, Divisione Biotecnologie e Agricoltura, C.R. Casaccia, 00060 Rome, Italy. Phone: 39-06-30486347. Fax: 39-06-30484741. E-mail: benvenutoe{at}casaccia.enea.it. Mailing address for Imerio Capone: Istituto Superiore di Sanità, Laboratorio di Virologia, 00161 Rome, Italy. Phone: 39-6-49903294. Fax: 39-6-49902097. E-mail: capone{at}iss.it.

Journal of Virology, September 2001, p. 8434-8439, Vol. 75, No. 18
0022-538X/01/$04.00+0   DOI: 10.1128/JVI.75.18.8434-8439.2001
Copyright © 2001, American Society for Microbiology. All rights reserved.


This article has been cited by other articles:



Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
J. Bacteriol. Mol. Cell. Biol. Microbiol. Mol. Biol. Rev.
Clin. Vaccine Immunol. ALL ASM JOURNALS

Copyright © 2001 by the American Society for Microbiology. All rights reserved.